338 related articles for article (PubMed ID: 38377822)
41. Modeling the CRL4A ligase complex to predict target protein ubiquitination induced by cereblon-recruiting PROTACs.
Bai N; Riching KM; Makaju A; Wu H; Acker TM; Ou SC; Zhang Y; Shen X; Bulloch DN; Rui H; Gibson BW; Daniels DL; Urh M; Rock BM; Humphreys SC
J Biol Chem; 2022 Apr; 298(4):101653. PubMed ID: 35101445
[TBL] [Abstract][Full Text] [Related]
42. A "Click Chemistry Platform" for the Rapid Synthesis of Bispecific Molecules for Inducing Protein Degradation.
Wurz RP; Dellamaggiore K; Dou H; Javier N; Lo MC; McCarter JD; Mohl D; Sastri C; Lipford JR; Cee VJ
J Med Chem; 2018 Jan; 61(2):453-461. PubMed ID: 28378579
[TBL] [Abstract][Full Text] [Related]
43. Recent progress in degradation of membrane proteins by PROTACs and alternative targeted protein degradation techniques.
Chen S; Cui J; Chen H; Yu B; Long S
Eur J Med Chem; 2023 Dec; 262():115911. PubMed ID: 37924709
[TBL] [Abstract][Full Text] [Related]
44. PROTAC-DB 2.0: an updated database of PROTACs.
Weng G; Cai X; Cao D; Du H; Shen C; Deng Y; He Q; Yang B; Li D; Hou T
Nucleic Acids Res; 2023 Jan; 51(D1):D1367-D1372. PubMed ID: 36300631
[TBL] [Abstract][Full Text] [Related]
45. Selective Wee1 degradation by PROTAC degraders recruiting VHL and CRBN E3 ubiquitin ligases.
Aublette MC; Harrison TA; Thorpe EJ; Gadd MS
Bioorg Med Chem Lett; 2022 May; 64():128636. PubMed ID: 35231578
[TBL] [Abstract][Full Text] [Related]
46. Recent advancements in the discovery of cereblon-based protease-targeted chimeras with potential for therapeutic intervention.
Singh H; Agrawal DK
Future Med Chem; 2022 Oct; 14(19):1403-1416. PubMed ID: 36047364
[TBL] [Abstract][Full Text] [Related]
47. Heterobifunctional Ligase Recruiters Enable pan-Degradation of Inhibitor of Apoptosis Proteins.
Ng YLD; Bricelj A; Jansen JA; Murgai A; Peter K; Donovan KA; Gütschow M; Krönke J; Steinebach C; Sosič I
J Med Chem; 2023 Apr; 66(7):4703-4733. PubMed ID: 36996313
[TBL] [Abstract][Full Text] [Related]
48. In situ albumin-binding and esterase-specifically cleaved BRD4-degrading PROTAC for targeted cancer therapy.
Cho H; Jeon SI; Shim MK; Ahn CH; Kim K
Biomaterials; 2023 Apr; 295():122038. PubMed ID: 36787659
[TBL] [Abstract][Full Text] [Related]
49. Structure-based discovery of SIAIS001 as an oral bioavailability ALK degrader constructed from Alectinib.
Ren C; Sun N; Kong Y; Qu X; Liu H; Zhong H; Song X; Yang X; Jiang B
Eur J Med Chem; 2021 May; 217():113335. PubMed ID: 33751979
[TBL] [Abstract][Full Text] [Related]
50. Piperlongumine conjugates induce targeted protein degradation.
Pei J; Xiao Y; Liu X; Hu W; Sobh A; Yuan Y; Zhou S; Hua N; Mackintosh SG; Zhang X; Basso KB; Kamat M; Yang Q; Licht JD; Zheng G; Zhou D; Lv D
Cell Chem Biol; 2023 Feb; 30(2):203-213.e17. PubMed ID: 36750097
[TBL] [Abstract][Full Text] [Related]
51. Recent Advances in PROTACs for Drug Targeted Protein Research.
Yao T; Xiao H; Wang H; Xu X
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142231
[TBL] [Abstract][Full Text] [Related]
52. Systematic exploration of different E3 ubiquitin ligases: an approach towards potent and selective CDK6 degraders.
Steinebach C; Ng YLD; Sosič I; Lee CS; Chen S; Lindner S; Vu LP; Bricelj A; Haschemi R; Monschke M; Steinwarz E; Wagner KG; Bendas G; Luo J; Gütschow M; Krönke J
Chem Sci; 2020 Apr; 11(13):3474-3486. PubMed ID: 33133483
[TBL] [Abstract][Full Text] [Related]
53. Tumor-targeted PROTAC prodrug nanoplatform enables precise protein degradation and combination cancer therapy.
Zou ZF; Yang L; Nie HJ; Gao J; Lei SM; Lai Y; Zhang F; Wagner E; Yu HJ; Chen XH; Xu ZA
Acta Pharmacol Sin; 2024 Apr; ():. PubMed ID: 38609561
[TBL] [Abstract][Full Text] [Related]
54. Cancer Selective Target Degradation by Folate-Caged PROTACs.
Liu J; Chen H; Liu Y; Shen Y; Meng F; Kaniskan HÜ; Jin J; Wei W
J Am Chem Soc; 2021 May; 143(19):7380-7387. PubMed ID: 33970635
[TBL] [Abstract][Full Text] [Related]
55. Delineating the role of cooperativity in the design of potent PROTACs for BTK.
Zorba A; Nguyen C; Xu Y; Starr J; Borzilleri K; Smith J; Zhu H; Farley KA; Ding W; Schiemer J; Feng X; Chang JS; Uccello DP; Young JA; Garcia-Irrizary CN; Czabaniuk L; Schuff B; Oliver R; Montgomery J; Hayward MM; Coe J; Chen J; Niosi M; Luthra S; Shah JC; El-Kattan A; Qiu X; West GM; Noe MC; Shanmugasundaram V; Gilbert AM; Brown MF; Calabrese MF
Proc Natl Acad Sci U S A; 2018 Jul; 115(31):E7285-E7292. PubMed ID: 30012605
[TBL] [Abstract][Full Text] [Related]
56. Design, synthesis and activity study of a novel PI3K degradation by hijacking VHL E3 ubiquitin ligase.
Wang H; Li C; Liu X; Ma M
Bioorg Med Chem; 2022 May; 61():116707. PubMed ID: 35344835
[TBL] [Abstract][Full Text] [Related]
57. PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics.
Khan S; He Y; Zhang X; Yuan Y; Pu S; Kong Q; Zheng G; Zhou D
Oncogene; 2020 Jun; 39(26):4909-4924. PubMed ID: 32475992
[TBL] [Abstract][Full Text] [Related]
58. Differential PROTAC substrate specificity dictated by orientation of recruited E3 ligase.
Smith BE; Wang SL; Jaime-Figueroa S; Harbin A; Wang J; Hamman BD; Crews CM
Nat Commun; 2019 Jan; 10(1):131. PubMed ID: 30631068
[TBL] [Abstract][Full Text] [Related]
59. Development of Phenyl-substituted Isoindolinone- and Benzimidazole-type Cereblon Ligands for Targeted Protein Degradation.
Nie X; Zhao Y; Tang H; Zhang Z; Liao J; Almodovar-Rivera CM; Sundaresan R; Xie H; Guo L; Wang B; Guan H; Xing Y; Tang W
Chembiochem; 2024 Feb; 25(4):e202300685. PubMed ID: 38116854
[TBL] [Abstract][Full Text] [Related]
60. Hi-JAK-ing the ubiquitin system: The design and physicochemical optimisation of JAK PROTACs.
Shah RR; Redmond JM; Mihut A; Menon M; Evans JP; Murphy JA; Bartholomew MA; Coe DM
Bioorg Med Chem; 2020 Mar; 28(5):115326. PubMed ID: 32001089
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
